Benefits
FDA Qualified Health Claim — UTI Prevention
FDA authorized qualified health claim (July 2020): consuming 500 mg cranberry dietary supplement daily 'may reduce the risk of recurrent UTI' in healthy women with prior UTI history. Exocyan™ at 500 mg meets this threshold. Foundational regulatory positioning.
E. coli Anti-Adhesion (PAC Mechanism)
Type-A PACs from cranberry inhibit adhesion of uropathogenic E. coli (UPEC) to bladder epithelium — preventing bacterial colonization. Distinct mechanism from antibiotics — reduces recurrence rather than treating active infection.
Recurrent UTI Reduction in Women
Multiple cranberry meta-analyses show modest to moderate reduction in UTI recurrence in women with prior UTI history. Effects most consistent with adequate PAC dose; dose-response relationship important.
High PAC Standardization (Up to 90%)
Exocyan™ can provide up to 90% PACs by Bate-Smith method or 20% by BL-DMAC method — among the most concentrated cranberry extracts available. Lower volume needed for equivalent PAC dose.
Authentication Verification
Nexira developed proprietary universal analytical method to verify Exocyan™ as Vaccinium macrocarpon — protecting against widespread cranberry adulteration with cheaper grape pomace, peanut skin extract, or other materials.
Mechanism of action
Type-A PAC Anti-Adhesion of E. coli
Cranberry PACs (specifically TYPE-A linkage proanthocyanidins, distinguished from type-B in other plant sources) bind to FimH adhesin on uropathogenic E. coli pili — preventing bacterial attachment to mannose receptors on bladder epithelium. Bacteria are flushed out in urine rather than colonizing. Foundational mechanism.
BL-DMAC vs Bate-Smith PAC Quantification
Two analytical methods quantify PACs differently: BL-DMAC measures total PAC content; Bate-Smith measures higher molecular weight fractions. Exocyan™ standardizes by both — provides regulatory and clinical specifications.
Polyphenol Co-Delivery
Whole cranberry powder provides additional polyphenols beyond PACs — flavonoids, anthocyanins, hydroxycinnamic acids — supporting overall vascular and urinary health.
Vitamin C and Acidic Urine Effect (Modest)
Cranberry contributes modest urine acidification; older theory of UTI prevention via acidification has been largely replaced by PAC anti-adhesion as primary mechanism.
Clinical trials
FDA review of cranberry clinical evidence supporting Qualified Health Claim authorization.
Healthy women with UTI history.
Limited but supportive evidence that 500 mg cranberry daily may reduce recurrent UTI risk. Established regulatory framework for evidence-based UTI prevention claims.
Meta-analyses of cranberry RCTs for UTI prevention.
Pooled across populations including women with recurrent UTIs.
Moderate evidence for UTI recurrence reduction in women with prior UTIs. Effect size variable; dose, PAC content, and population characteristics matter. Generally supportive but inconsistent.
About this ingredient
EXOCYAN™ is a STANDARDIZED CRANBERRY EXTRACT (VACCINIUM MACROCARPON) manufactured by NEXIRA (France).
KEY ACTIVE: TYPE-A PROANTHOCYANIDINS (PACs) — distinct chemical structure from type-B PACs in other plant sources; specifically responsible for E. coli anti-adhesion activity in urinary tract. CRANBERRY BOTANY: Vaccinium macrocarpon is North American native cranberry; large red berry; harvested by wet (flooding bogs) or dry methods; primary US/Canadian commercial production. EXOCYAN™ DISTINCTIONS: (1) HIGH PAC STANDARDIZATION — up to 90% PACs by Bate-Smith method, 20% by BL-DMAC method; (2) NEXIRA PROPRIETARY AUTHENTICATION METHOD — verifies Vaccinium macrocarpon identity; protects against widespread cranberry adulteration; (3) MULTIPLE GRADES — organic available; solvent-free available; (4) FDA QUALIFIED HEALTH CLAIM compliance at 500 mg dose; (5) USE OF POMACE OR JUICE source materials with various processing options.
EVIDENCE-BASED USES: (1) UTI PREVENTION in women with prior UTI history (FDA Qualified Health Claim); (2) Recurrent UTI risk reduction; (3) Urinary tract health support; (4) Adjunct to antibiotic treatment for prevention.
CRITICAL CAUTIONS: (1) ACTIVE UTI vs PREVENTION — cranberry is for PREVENTION not TREATMENT of active UTI; active UTI requires antibiotic evaluation by healthcare provider; (2) PAC ANALYTICAL METHODS — BL-DMAC and Bate-Smith methods produce different numerical PAC values — verify product specifies which method and threshold; (3) ADULTERATION — cranberry market historically plagued by adulteration with cheaper sources (grape pomace, peanut skin, peony, other PAC-containing materials); reputable suppliers use authentication methods like Nexira's; (4) DOSE — 500 mg/day for FDA Qualified Health Claim; higher PAC concentration products allow lower doses; (5) WARFARIN INTERACTION — older concern about INR elevation; modern systematic reviews suggest minimal effect for most patients; consult prescriber if combining; (6) PREGNANCY/LACTATION — cranberry generally considered safe; widely used; (7) CHILDREN — appropriate at proportional doses; pediatric UTI management requires medical evaluation; (8) CALCIUM-OXALATE STONES — cranberry oxalate content; juice has more concern than concentrated extract; consult if stone history; (9) DURATION — UTI prevention requires ongoing daily use; not pulsed dosing; (10) NEXIRA SUSTAINABILITY — works with North American cranberry growers; multiple processing options; (11) JUICE VS EXTRACT — cranberry juice cocktail typically too dilute for clinical UTI prevention; concentrated extracts provide standardized PAC dose; (12) FOR RECURRENT UTI — comprehensive approach including hydration, hygiene, and post-coital voiding (where relevant) supplemented by Exocyan™ for prevention; (13) BRAND VERIFICATION — Exocyan™ is Nexira trademark; clinical evidence specific to standardized form; generic cranberry products vary widely in PAC content; (14) For UTI MANAGEMENT — Exocyan is among the better-evidenced cranberry options due to standardization; reasonable inclusion in UTI prevention protocols for women with recurrent infections.